Regulatory Considerations on Endpoints in Ovarian Cancer Drug Development

Cancer - United States
doi 10.1002/cncr.30652
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Drug Development and Registration: Challenges and Opportunities in Ovarian Cancer

Cancer
Cancer ResearchOncology
2017English

Intracellular Trafficking Considerations in the Development of Natural Ligand-Drug Molecular Conjugates for Cancer

Annals of Biomedical Engineering
Biomedical Engineering
2011English

Drug Combo May Be Effective in Ovarian Cancer

Cancer Discovery
Oncology
2014English

Role of Model‐Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling

Journal of Clinical Pharmacology
Pharmacology
2019English

Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2018English

Diagnostics in Cancer Drug Development

Expert Review of Molecular Diagnostics
Forensic MedicineGeneticsPathologyMolecular MedicineMolecular Biology
2004English

Pharmacodynamic Endpoints as Clinical Trial Objectives to Answer Important Questions in Oncology Drug Development

Seminars in Oncology
OncologyHematology
2016English

Nano Drug Delivery Systems for Ovarian Cancer Therapy

Integrative Cancer Science and Therapeutics
2017English

Molecular Imaging in Cancer Drug Development

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy